Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

BACKGROUND: Breast cancer is the second most common cancer worldwide, the most common among women, and the most frequent cause of death among women in less developed regions. Trastuzumab is a humanized monoclonal antibody that downregulates the extracellular domain of the HER2 protein. Using trastuz...

Descripción completa

Detalles Bibliográficos
Autores principales: Gershon, Noga, Berchenko, Yakir, Hall, Peter S., Goldstein, Daniel A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396469/
https://www.ncbi.nlm.nih.gov/pubmed/30867655
http://dx.doi.org/10.1186/s12962-019-0174-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396469/
https://www.ncbi.nlm.nih.gov/pubmed/30867655
http://dx.doi.org/10.1186/s12962-019-0174-7

Ejemplares similares